Literature DB >> 19443863

Bone loss in inflammatory disorders.

R Hardy1, M S Cooper.   

Abstract

Chronic inflammatory diseases of almost any cause are associated with bone loss. Bone loss is due to direct effects of inflammation, poor nutrition, reduced lean body mass, immobility and the effects of treatments, especially glucocorticoids. These mechanisms are complex and interrelated but are ultimately mediated through effects on the bone remodelling cycle. Inflammatory disease can increase bone resorption, decrease bone formation but most commonly impacts on both of these processes resulting in an uncoupling of bone formation from resorption in favour of excess resorption. This review will illustrate these interactions between inflammation and bone metabolism and discuss how these are, and might be, manipulated as therapies for inflammation related bone loss.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443863     DOI: 10.1677/JOE-08-0568

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  118 in total

Review 1.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

2.  Association between the ACE gene I/D polymorphism and osteoporosis in a Turkish population.

Authors:  B Cakmak; A Inanir; N Karakus; O Ates; S Yigit
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

3.  Mesenchymal stem cells, aging and regenerative medicine.

Authors:  Chiara Raggi; Anna C Berardi
Journal:  Muscles Ligaments Tendons J       Date:  2012-10-16

4.  Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women.

Authors:  Maria Swanberg; Fiona McGuigan; Kaisa K Ivaska; Paul Gerdhem; Ulf H Lerner; Richard Bucala; George Kuchel; Anne Kenny; Kristina Akesson
Journal:  Bone       Date:  2010-05-12       Impact factor: 4.398

Review 5.  Influence of body weight on bone mass, architecture and turnover.

Authors:  Urszula T Iwaniec; Russell T Turner
Journal:  J Endocrinol       Date:  2016-06-27       Impact factor: 4.286

6.  Glucocorticoid-induced osteoporosis: how best to avoid fractures.

Authors:  Mark S Cooper
Journal:  Ther Adv Chronic Dis       Date:  2010-01       Impact factor: 5.091

7.  The macroscopic and histomorphological properties of periosteal rib lesions and its relation with disease duration: evidence from the Luis Lopes Skeletal Collection (Lisbon, Portugal).

Authors:  Sandra Assis; Anne Keenleyside
Journal:  J Anat       Date:  2019-01-31       Impact factor: 2.610

8.  Association between malnutrition-inflammation score and risk of subsequent self-reported bone fractures in prevalent kidney transplant recipients.

Authors:  A Gaipov; O Cseprekal; P K Potukuchi; K Kabulbayev; A Remport; Z Mathe; M Talwar; V Balaraman; T Fülöp; J D Eason; I Mucsi; C P Kovesdy; M Z Molnar
Journal:  Osteoporos Int       Date:  2018-11-19       Impact factor: 4.507

9.  Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

Authors:  A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2012-07-27       Impact factor: 5.958

Review 10.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.